Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis
作者:Hualong Mo、Ruiqiang Zhang、Yajun Chen、ShuTing Li、Yao Wang、Wenbo Zou、Qiman Lin、Deng-Gao Zhao、Yarong Du、Kun Zhang、Yan-Yan Ma
DOI:10.1016/j.ejmech.2022.114705
日期:2022.12
deacetylase (HDAC) and autophagy inhibitor has been considered as a novel cancer therapeutic strategy. To find novel HDAC inhibitors that can inhibit autophagy, several new series of oxazole- and thiazole-based HDAC inhibitors were designed and synthesized by replacing the phenyl cap in SAHA with 5-phenyloxazoles and 5-phenylthiazoles. The representative oxazole derivative, compound 21, showed better enzymatic
组蛋白去乙酰化酶 (HDAC) 和自噬抑制剂的组合被认为是一种新的癌症治疗策略。为了寻找能够抑制自噬的新型 HDAC 抑制剂,通过用 5-苯基恶唑和 5-苯基噻唑代替 SAHA 中的苯基帽,设计并合成了几个新系列的基于恶唑和噻唑的 HDAC 抑制剂。具有代表性的恶唑衍生物化合物21显示出比 SAHA(伏立诺他)更好的酶抑制活性。在多种肿瘤细胞系中,化合物21诱导 G2/M 细胞周期停滞,其抗增殖活性比 SAHA 好 10 倍。Western印迹分析表明化合物21可显着提高微管蛋白、组蛋白 H3 和组蛋白 H4 的乙酰化水平。与 SAHA 相反,发现化合物21可抑制自噬。此外,化合物21通过 Bax/Bcl-2 和 caspase-3 途径诱导细胞凋亡。最终,在 A549 异种移植模型中,化合物21表现出比 SAHA 更高的口服抗肿瘤效力。我们的研究结果表明,化合物21可以进一步开发为一种有前途的抗癌剂。